SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express... ( NATICK Mass. and BARCELONA Spain ...)

SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents

Date:5/13/2008

NATICK, Mass. and BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed two-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety and efficacy of the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System and reinforce the growing body of positive clinical evidence for the XIENCE(TM) V (PROMUS(TM)) Everolimus-Eluting Coronary Stent System. The results were presented at the 2008 EuroPCR Scientific Program in Barcelona by Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation in New York, and the Principal Investigator of the SPIRIT III Trial.

The results demonstrated comparable safety and efficacy rates through two years for the XIENCE V (PROMUS) and TAXUS Express Stents. The Ischemia-Driven Target Lesion Revascularization (TLR) rate for the XIENCE V (PROMUS) Stent was 4.3% while the TAXUS Express Stent was 6.9% (p=0.07). The overall Major Adverse Cardiac Event, (MACE a composite endpoint of Cardiac Death, Myocardial Infarction and TLR) rate was 7.3% for the XIENCE V (PROMUS) Stent and 12.8% for the TAXUS Express Stent (p=0.004). In addition, stent thrombosis rates using the ARC (Academic Research Consortium) definite/probable definition were low for the XIENCE V (PROMUS) and the TAXUS Express Stents (1.3% and 1.7%, p=0.77).

"We are very pleased that both the TAXUS Express and PROMUS Stents continue to perform so well in the SPIRIT III trial, adding to the extensive body of clinical evidence reinforcing the excellent safety and efficacy of the market-leading TAXUS Stent and the growing body of positive clinical evidence for the PROMUS Stent at two years,"
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Exelixis Announces First Quarter 2008 Financial Results
10. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
11. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update

Post Your Comments:

SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express...( NATICK Mass. and BARCELONA Spain ...),Health